Baird Medical (XFIN)

Founded in 2012, Baird Medical stands as China's leading medical device company specializing in thyroid ablation technology. We are dedicated to revolutionizing the treatment of thyroid nodules through innovative, minimally invasive thermal ablation procedures, significantly enhancing patients' quality of life.

We are proud to be the first company in China to receive a class III registration certificate for the microwave ablation of thyroid nodules.

Baird Medical is committed to advancing patient care through ongoing physician education, ensuring that medical professionals are equipped with the latest knowledge and techniques in thyroid treatment. (Source: Company Website 09.20.24)

Beyond Air, Inc. (XAIR)

Beyond Air is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval for its first system, LungFit® PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others. Also, the Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. (Source: Company Website 08.26.24)

Biofrontera Inc. (BFRI)

Biofrontera is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care. (Source: Company Website 08.06.24)

Biofrontera, Inc. was founded in March 2015 to commercialize the FDA-approved flagship drug Ameluz®  (aminolevulinic acid hydrochloride) gel, 10%, in the United States. In 2019, Biofrontera Inc. expanded its U.S.-product portfolio with the FDA-approved drug Xepi® (ozenoxacin) cream, 1%. With both FDA-approved products, Biofrontera Inc. is ideally positioned for sustainable growth.

BioRestorative Therapies, Inc. (BRTX)

BioRestorative Therapies was founded by scientists and researchers committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.
Our advances in stem cell biology and delivery protocols harbor great promise in conditioning our bodies’ own regenerative potential to treat major diseases more effectively than current interventions.

Today, BioRestorative is actively developing programs that aim to dramatically increase quality of care for both (i) chronic back pain caused by disc degeneration, as well as (ii) metabolic disorders including obesity and diabetes. (Source: Company Website 08.06.24)

Candel Therapeutics, Inc. (CADL)

The cancer treatment paradigm has shifted dramatically, providing evidence that the immune system can be educated to recognize and eliminate the patient’s tumor cells. At Candel Therapeutics, we are developing viral immunotherapies that induce immunogenic cell death in cancer cells at the site of injection, unmasking tumor antigens and neo-antigens within an activated microenvironment. This process leads to a systemic, durable immune response against the tumor through in situ vaccination, with the potential to change disease outcomes across a variety of indications. Candel’s product candidates are designed to improve survival while maintaining quality of life in patients with early- to late-stage disease.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. (Source: Company Website 08..7.24)

Cellectar Biosciences, Inc. (CLRB)

Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.  (Source: Company Website 08.06.24)

CervoMed Inc. (CRVO)

CervoMed is a clinical stage company dedicated to the development and commercialization of drug treatments for neurodegenerative diseases with a focus on the early stages of the neurodegenerative process. (Source: Company Website 08.08.24)

Chemomab Therapeutics Ltd. (CMMB)

Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. (Source: Company Website 08.27.24)

Cingulate Inc. (CING)

Cingulate® (CTx®) is a Phase 3 clinical stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build and advance a pipeline of branded next-generation pharmaceutical products. These will be designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas, such as anxiety disorders, where PTR™ technology may be employed to develop future product candidates. (Source: Company Website 08.13.24)

Cognition Therapeutics, Inc. (CGTX)

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company developing oral medications designed to treat neurodegenerative and neuro-ophthalmic disorders
The sheer number of patients and caregivers affected by the combined burden of Alzheimer’s disease, dementia with Lewy bodies (DLB), and dry age-related macular degeneration (dry AMD) is the driving force behind Cognition’s mission to develop safe, effective, easy-to-administer treatment options that slow the progression of these life-altering diseases. ( Source: Company Website 08.08.24)

Fortress Biotech, Inc. (FBIO)

Fortress Biotech, Inc. is an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed drugs and development-stage drug candidates. We develop and commercialize products both within our company and through our partner companies. (Source: Company Website 08.26.24)

Gain Therapeutics, Inc. (GANX)

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation. Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma exposure in the projected therapeutic range, CNS exposure, and target engagement and modulation of GCase enzyme. Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function.

Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.”

GeoVax Labs, Inc. (GOVX)

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and therapy for advanced head and neck cancer. Additional development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, and Marburg), malaria and Zika virus, as well as therapies for various solid tumors. (Source: Company Website 08.06.24)

GT Biopharma, Inc. (GTBP)

GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE®) technology. TriKE® therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells. (Source: Company Website 08.09.24)

iRadimed Corp. (IRMD)

IRadimed Corporation (NASDAQ: IRMD) develops, manufactures, and markets innovative MRI compatible medical devices. We are the only known provider of non-magnetic intravenous (IV) infusion pump systems and non-magnetic patient vital signs monitors specifically designed for use during magnetic resonance imaging (MRI) procedures. IRadimed was founded in 2005 and became public in 2014 and currently holds leading market positions across the globe. This growth minded company is headquartered in Winter Springs, Florida. (Source: Company Website: 08.26.24)

Journey Medical Corp. (DERM)

Journey Medical is focused on strategically identifying, acquiring, and successfully commercializing innovative and differentiated dermatology products. The Journey team is comprised of industry experts with decades of experience commercializing some of the most successful prescription dermatology brands. Our market knowledge and experience allow us to identify undervalued assets and future opportunities, then commercialize these opportunities through a best-in-dermatology marketing and sales organization. (Source: Company Website 08.27.24)

Longeveron Inc (LGVN)

We are a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions.

Our lead investigational product is Lomecel-B™, which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult diseases and conditions associated with aging. (Source: Company Website 08.15.24)

Moleculin Biotech, Inc. (MBRX)

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. (Source: Company Website 08.06.24)

Nuvectis Pharma, Inc. (NVCT)

NUVECTIS PHARMA, INC. is a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. (Source: Company Webiste 08.06.24)

Nuwellis, Inc. (NUWE)

Nuwellis is a commercial stage company focused on commercializing the Aquadex SmartFlow® System. Our objective is to improve the quality of life for patients with heart failure and related conditions, such as fluid overload. (Source: Company Website 08.05.24)

Orthofix Medical Inc. (OFIX)

Orthofix is a leading global spine and orthopedics company with a comprehensive portfolio of biologics, innovative spinal hardware, bone growth therapies, specialized orthopedic solutions, and a leading surgical navigation system. Our products are distributed in more than 60 countries worldwide.

Our medical device company is headquartered in Lewisville, Texas, where it conducts general business, product development, medical education and manufacturing, and has primary offices in Carlsbad, CA, with a focus on spinal product innovation and surgeon education, and Verona, Italy, with an emphasis on product innovation, production, and medical education for orthopedics. Our combined company’s global R&D, commercial and manufacturing footprint also includes facilities and offices in Irvine, CA, Toronto, Canada, Sunnyvale, CA, Maidenhead, UK, Munich, Germany, Paris, France, and São Paulo, Brazil. (Source: Company Website 08.19.24)

Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics is a biopharmaceutical company striving to calm the storm that causes seizures by developing new medicines for epilepsies and brain conditions. Today, nearly 50 million people across the world live with epilepsies and seizures. Approximately half these patients take five or more medicines, yet they still experience seizures. Additionally, some current anti-seizure medicines can also be hard to tolerate as they cause side effects that can diminish overall quality of life.  (Source: Company Website 08.08.24)

Replimune Group, Inc. (REPL)

Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, generating a powerful patient-specific, systemic immune response.

Oncolytic immunotherapy enhances the effectiveness of immune checkpoint blockade and is expected to become the second cornerstone of immuno-oncology (IO) approaches, moving beyond incremental improvements in cancer treatment to help more patients overcome their disease. (Source: Company Website 08.14.24)

Reviva Pharmaceuticals Holdings, Inc. (RVPH)

We are a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases.

Our pipeline currently has two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house using our chemical genomics driven technology platform.
We have been granted composition of matter patents for both RP5063 and R1208 in the United States (U.S.), Europe, and several other countries. (Source: Company Website 08.09.24)

Sensus Healthcare, Inc. (SRTS)

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally invasive, and cost-effective treatments for both oncological and non-oncological conditions.

Sensus offers its proprietary low-energy photon radiotherapy known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world. (Source: Company Website 09.16.24)

TFF Pharmaceuticals, Inc. (TFFP)

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicines into potent dry powder formulations for better efficacy, safety and stability. The company’s versatile Thin Film Freezing (TFF) technology platform has broad applicability to convert any drug, including vaccines, small and large molecules and biologics, into an elegant dry powder highly advantageous for inhalation, with improved absorption so drugs can also be delivered to the eyes, nose and topically to the skin. TFF has two lead drug candidates in the clinic: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder, and continues to expand its pipeline by collaborating with a broad array of pharmaceutical companies, academic institutions and government partners to revolutionize healthcare around the globe. The TFF Platform is protected by 120+ patents issued or pending in the U.S. and internationally.  (Source: Company Website 08.06.24)